Division of Digestive Disease, Emory University Hospital, Atlanta, GA.
Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA.
Liver Transpl. 2018 Dec;24(12):1665-1672. doi: 10.1002/lt.25351.
Posttransplant diabetes mellitus (PTDM), an increasingly recognized complication of solid organ transplantation, is associated with increased morbidity and mortality following liver transplantation (LT). Hepatitis C virus (HCV) infection is a consistent and modifiable risk factor for PTDM. Prior studies have demonstrated improvement in glucose metabolism following sustained virological response (SVR). However, the effect of SVR on the incidence of PTDM has not been previously investigated in a large cohort of LT recipients. We performed a single-center retrospective cohort study of LT recipients with HCV from January 1, 2010 to June 30, 2015 to compare the risk of sustained posttransplant diabetes mellitus (s-PTDM) prior to and following SVR. SVR was treated as a discrete time varying exposure. The s-PTDM was defined as de novo diabetes mellitus following LT of a >6-month duration. Univariate and multivariate Cox proportional hazards models were used to compare crude and adjusted time to s-PTDM prior to and following SVR. There were 256 eligible LT recipients analyzed. Median follow-up was 41.2 months. Overall, 31 (12.1%) and 178 (69.5%) patients achieved SVR prior to LT and following LT, respectively. During follow-up, 71 (27.7%) patients developed s-PTDM. The incidence of s-PTDM was greatest in the first year after LT. After adjustment for potential confounders, SVR was associated with a significantly reduced risk of s-PTDM (HR, 0.40; P = 0.048). In conclusion, eradication of HCV is independently associated with a reduced incidence of s-PTDM. This benefit appears to be most influenced by pre-LT SVR and persists throughout the post-LT period. Given the association between PTDM and posttransplant morbidity and mortality, these data provide another motivator for pre-LT or early post-LT treatment of HCV.
移植后糖尿病(PTDM)是实体器官移植后越来越被认识到的一种并发症,与肝移植(LT)后的发病率和死亡率增加有关。丙型肝炎病毒(HCV)感染是 PTDM 的一个一致且可改变的危险因素。先前的研究表明,持续病毒学应答(SVR)后葡萄糖代谢得到改善。然而,SVR 对 LT 受者中 PTDM 发生率的影响尚未在大型 LT 受者队列中进行研究。我们对 2010 年 1 月 1 日至 2015 年 6 月 30 日期间患有 HCV 的 LT 受者进行了单中心回顾性队列研究,以比较 SVR 前后持续移植后糖尿病(s-PTDM)的风险。SVR 被视为一个离散的时间变化暴露。s-PTDM 被定义为 LT 后 >6 个月发生的新发糖尿病。使用单变量和多变量 Cox 比例风险模型比较 SVR 前后 s-PTDM 的粗风险和调整风险。分析了 256 名符合条件的 LT 受者。中位随访时间为 41.2 个月。总体而言,分别有 31 名(12.1%)和 178 名(69.5%)患者在 LT 前和 LT 后达到 SVR。在随访期间,有 71 名(27.7%)患者发生 s-PTDM。s-PTDM 的发生率在 LT 后第一年最高。在调整潜在混杂因素后,SVR 与 s-PTDM 的风险显著降低相关(HR,0.40;P = 0.048)。总之,HCV 的根除与 s-PTDM 发生率的降低独立相关。这种益处似乎主要受到 LT 前 SVR 的影响,并在 LT 后持续存在。鉴于 PTDM 与移植后发病率和死亡率之间的关联,这些数据为 LT 前或 LT 后早期治疗 HCV 提供了另一个动力。